Day 1 – world lung

  • EGFR inhibitors can have modest efficacy in uncommon eEGFR mutations but not in┬áT790m de novo mutations and exon 20 insertions (analysis of LUX studied with afatinib
  • 4% risk of dangerous interstitial lung disease with EGFR TKIs in Japanese populations with a mortality of 1.5% . Note this risk incidence does not apply to Caucasian population